Certara (CERT) Expected to Post Quarterly Earnings on Tuesday

Certara (NASDAQ:CERT) is projected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.10 per share and revenue of $98.0870 million for the quarter. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara’s revenue was up .8% on a year-over-year basis. During the same quarter last year, the business earned $0.14 EPS. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Price Performance

NASDAQ CERT traded up $0.40 during midday trading on Tuesday, hitting $8.15. The company had a trading volume of 1,096,341 shares, compared to its average volume of 3,657,619. The firm has a 50-day moving average price of $6.06 and a 200-day moving average price of $6.62. The company has a market capitalization of $1.27 billion, a PE ratio of -81.58 and a beta of 1.46. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $4.45 and a twelve month high of $13.88.

Analysts Set New Price Targets

CERT has been the topic of a number of recent analyst reports. BMO Capital Markets decreased their price target on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Tuesday, May 12th. Barclays reduced their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Craig Hallum decreased their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. KeyCorp dropped their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.85.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CERT. AQR Capital Management LLC bought a new position in shares of Certara in the first quarter worth about $259,000. Goldman Sachs Group Inc. lifted its stake in Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Certara by 29.3% during the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.